The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
Abstract
Summary: Although TNFRSF 17 (also designated as B‐cell maturation antigen (BCMA)) is expressed on tumour cells in B‐cell malignancies, it has not been found in serum. The present study found that BCMA concentrations were higher in the supernatants of cultured bone marrow mononuclear cells from multiple myeloma (MM) patients than in healthy subjects. Serum BCMA levels were measured in samples from MM patients (n = 209), monoclonal gammopathy of undetermined significance (MGUS) individuals (n = 23) and age‐matched controls (n = 40). BCMA was detected in the serum of untreated MM patients (n = 50) and levels were higher than in MGUS patients (P = 0·0157) and healthy subjects (P < 0·0001). Serum BCMA levels were higher among patients with progressive disease (n = 80) compared to those with responsive disease (n = 79; P = 0·0038). Among all MM patients, overall survival was shorter among patients whose serum BCMA levels were above the median (P = 0·001). We also demonstrated that sera from mice with human MM xenografts contained human BCMA, and levels correlated with the change in tumour volume in response to melphalan or cyclophosphamide with bortezomib. These results suggest that serum BCMA levels may be a new biomarker for monitoring disease status and overall survival of MM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International Staging System for Multiple Myeloma
Greipp, P. R., Miguel, J. S., Durie, B. G. M., Crowley, J. J., Barlogie, B., Bladé, J., Boccadoro, M., Child, J. A., Avet-Loiseau, H., Kyle, R. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.242 · Cited by 2,974
Self-citationThe International Myeloma Working Group (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04355.x · Cited by 2,321
The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death
Smith, C. A., Farrah, T., & Goodwin, R. G. (1994) · Cell · doi:10.1016/0092-8674(94)90372-7 · Cited by 1,887
Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations
Mackay, F., Woodcock, S. A., Lawton, P., Ambrose, C., Baetscher, M., Schneider, P., Tschopp, J., & Browning, J. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.11.1697 · Cited by 1,480
TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease
Gross, J. A., Johnston, J., Mudri, S., Enselman, R., Dillon, S. R., Madden, K., Xu, W., Parrish-Novak, J., Foster, D., Lofton-Day, C., et al. (2000) · Nature · doi:10.1038/35010115 · Cited by 1,174
BCMA Is Essential for the Survival of Long-lived Bone Marrow Plasma Cells
O'Connor, B. P., Raman, V. S., Erickson, L. D., Cook, W. J., Weaver, L. K., Ahonen, C., Lin, L.-L., Mantchev, G. T., Bram, R. J., & Noelle, R. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031330 · Cited by 1,128
Rajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
BAFF-R, a Newly Identified TNF Receptor That Specifically Interacts with BAFF
Thompson, J. S., Bixler, S. A., Qian, F., Vora, K., Scott, M. L., Cachero, T. G., Hession, C., Schneider, P., Sizing, I. D., Mullen, C., et al. (2001) · Science · doi:10.1126/science.1061965 · Cited by 889
Cheema, G. S., Roschke, V., Hilbert, D. M., & Stohl, W. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1313::aid-art223>3.0.co;2-s · Cited by 802
Cutting Edge: A Role for B Lymphocyte Stimulator in Systemic Lupus Erythematosus
Zhang, J., Roschke, V., Baker, K. P., Wang, Z., Alarcón, G. S., Fessler, B. J., Bastian, H., Kimberly, R. P., & Zhou, T. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.6 · Cited by 734
Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren’s syndrome
Groom, J., Kalled, S. L., Cutler, A. H., Olson, C., Woodcock, S. A., Schneider, P., Tschopp, J., Cachero, T. G., Batten, M., Wheway, J., et al. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0214121 · Cited by 712
The soluble interleukin 6 receptor: mechanisms of production and implications in disease
JONES, S. A., HORIUCHI, S., TOPLEY, N., YAMAMOTO, N., & FULLER, G. M. (2001) · The FASEB Journal · doi:10.1096/fj.99-1003rev · Cited by 623
Moreaux, J., Legouffe, E., Jourdan, E., Quittet, P., Rème, T., Lugagne, C., Moine, P., Rossi, J.-F., Klein, B., & Tarte, K. (2004) · Blood · doi:10.1182/blood-2003-06-1984 · Cited by 558
Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival
Novak, A. J., Darce, J. R., Arendt, B. K., Harder, B., Henderson, K., Kindsvogel, W., Gross, J. A., Greipp, P. R., & Jelinek, D. F. (2004) · Blood · doi:10.1182/blood-2003-06-2043 · Cited by 554
Extensive Immunoglobulin Production Sensitizes Myeloma Cells for Proteasome Inhibition
Meister, S., Schubert, U., Neubert, K., Herrmann, K., Burger, R., Gramatzki, M., Hahn, S., Schreiber, S., Wilhelm, S., Herrmann, M., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2258 · Cited by 410
Seshasayee, D., Valdez, P., Yan, M., Dixit, V. M., Tumas, D., & Grewal, I. S. (2003) · Immunity · doi:10.1016/s1074-7613(03)00025-6 · Cited by 400
Thompson, J. S., Schneider, P., Kalled, S. L., Wang, L., Lefevre, E. A., Cachero, T. G., MacKay, F., Bixler, S. A., Zafari, M., Liu, Z.-Y., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.1.129 · Cited by 394
Yan, M., Brady, J. R., Chan, B., Lee, W. P., Hsu, B., Harless, S., Cancro, M., Grewal, I. S., & Dixit, V. M. (2001) · Current Biology · doi:10.1016/s0960-9822(01)00481-x · Cited by 392
APRIL and TALL-1 and receptors BCMA and TACI: system for regulating humoral immunity
Yu, G., Boone, T., Delaney, J., Hawkins, N., Kelley, M., Ramakrishnan, M., McCabe, S., Qiu, W.-R., Kornuc, M., Xia, X.-Z., et al. (2000) · Nature Immunology · doi:10.1038/79802 · Cited by 361
Xu, S., & Lam, K.-P. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.12.4067-4074.2001 · Cited by 267
Rennert, P., Schneider, P., Cachero, T. G., Thompson, J., Trabach, L., Hertig, S., Holler, N., Qian, F., Mullen, C., Strauch, K., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.11.1677 · Cited by 252
Wu, Y., Bressette, D., Carrell, J. A., Kaufman, T., Feng, P., Taylor, K., Gan, Y., Cho, Y. H., Garcia, A. D., Gollatz, E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m005224200 · Cited by 245
Chiu, A., Xu, W., He, B., Dillon, S. R., Gross, J. A., Sievers, E., Qiao, X., Santini, P., Hyjek, E., Lee, J.-W., et al. (2007) · Blood · doi:10.1182/blood-2006-04-015958 · Cited by 228
The BCMA gene, preferentially expressed during B lymphoid maturation, is bidirectionally transcribed
Laabi, Y., Gras, M.-P., Brouet, J.-C., Berger, R., Larsen, C.-J., & Tsapis, A. (1994) · Nucleic Acids Research · doi:10.1093/nar/22.7.1147 · Cited by 211
APRIL-Deficient Mice Have Normal Immune System Development
Varfolomeev, E., Kischkel, F., Martin, F., Seshasayee, D., Wang, H., Lawrence, D., Olsson, C., Tom, L., Erickson, S., French, D., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.3.997-1006.2004 · Cited by 183
Immunoglobulin synthesis and total body tumor cell number in IgG multiple myeloma
Salmon, S. E., & Smith, B. A. (1970) · Journal of Clinical Investigation · doi:10.1172/jci106327 · Cited by 181
Selectivity of BAFF/BLyS and APRIL for Binding to the TNF Family Receptors BAFFR/BR3 and BCMA
Day, E. S., Cachero, T. G., Qian, F., Sun, Y., Wen, D., Pelletier, M., Hsu, Y.-M., & Whitty, A. (2005) · Biochemistry · doi:10.1021/bi048227k · Cited by 176
Global Gradients of Coral Exposure to Environmental Stresses and Implications for Local Management
Maina, J., McClanahan, T. R., Venus, V., Ateweberhan, M., & Madin, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023064 · Cited by 162
Laâbi, Y., Gras, M.-P., Carbonnel, F., Brouet, J. C., Berger, R., Larsen, C., & Tsapis, A. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05482.x · Cited by 157
Identification of immature and mature myeloma cells in the bone marrow of human myelomas
Kawano, M., Huang, N., Harada, H., Harada, Y., Sakai, A., Tanaka, H., Iwato, K., & Kuramoto, A. (1993) · Blood · doi:10.1182/blood.v82.2.564.564 · Cited by 136
Zaanen, V., Lokhorst, Aarden, Rensink, Warnaar, Lelie, V. D., & van Oers, M. H. J. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00835.x · Cited by 127
A clinically relevant SCID-hu in vivo model of human multiple myeloma
Tassone, P., Neri, P. E., Carrasco, D. R., Burger, R., Goldmacher, V. S., Fram, R. J., Munshi, V. N., Shammas, M. A., Catley, L. P., Jacob, G. S., et al. (2005) · Blood · doi:10.1182/blood-2005-01-0373 · Cited by 115
Bellucci, R., Alyea, E. P., Chiaretti, S., Wu, C. J., Zorn, E., Weller, E. A., Wu, B., Canning, C. M., Schlossman, R. L., Munshi, N. C., et al. (2005) · Blood · doi:10.1182/blood-2004-11-4463 · Cited by 101
Elsawa, S. F., Novak, A. J., Grote, D. M., Ziesmer, S. C., Witzig, T. E., Kyle, R. A., Dillon, S. R., Harder, B., Gross, J. A., & Ansell, S. M. (2005) · Blood · doi:10.1182/blood-2005-09-3552 · Cited by 94
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Ryan, M. C., Hering, M. A., Peckham, D., McDonagh, C. F., Brown, L. L., Kim, K. M., Meyer, D. L., Zabinski, R. F., Grewal, I. S., & Carter, P. J. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0464 · Cited by 89
The proteasome inhibitor CEP‐18770 enhances the anti‐myeloma activity of bortezomib and melphalan
Sanchez, E., Li, M., Steinberg, J. A., Wang, C., Shen, J., Bonavida, B., Li, Z., Chen, H., & Berenson, J. R. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.08008.x · Cited by 81
Self-citationTHE FORMATION OF MYELOMA PROTEIN BY A MOUSE PLASMA CELL TUMOR
Nathans, D., Fahey, J. L., & Potter, M. J. (1958) · The Journal of Experimental Medicine · doi:10.1084/jem.108.1.121 · Cited by 71
Stephens, O., Zhang, Q., Qu, P., Zhou, Y., Chavan, S. S., Tian, E., Williams, D. R., Epstein, J., Barlogie, B., & Shaughnessy, J. D. (2011) · Blood · doi:10.1182/blood-2011-07-367052 · Cited by 65
Maia, S., Pelletier, M. R., Ding, J., Hsu, Y., Sallan, S. E., Rao, S. P., Nadler, L. M., & Cardoso, A. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020787 · Cited by 56
Why better prognostic factors for multiple myeloma are needed [editorial] [see comments]
Kyle, R. A. (1994) · Blood · doi:10.1182/blood.v83.7.1713.1713 · Cited by 54
Sensitive inhibitory effect of interferon-alpha on M-protein secretion of human myeloma cells
Tanaka, H., Tanabe, O., Iwato, K., Asaoku, H., Ishikawa, H., Nobuyoshi, M., Kawano, M., & Kuramoto, A. (1989) · Blood · doi:10.1182/blood.v74.5.1718.1718 · Cited by 37
Shaw, G. R. (2006) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2006-130-1212-npcmem · Cited by 34
Animal Models of Multiple Myeloma and Their Utility in Drug Discovery
Campbell, R. A., & Berenson, J. R. (2008) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph1409s40 · Cited by 12
Self-citation
Cited by
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
Rodriguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A. K., Manier, S., Callander, N., Costa, L. J., Vij, R., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2213614 · Cited by 781
B cell maturation antigen–specific CAR T cells are clinically active in multiple myeloma
Cohen, A. D., Garfall, A. L., Stadtmauer, E. A., Melenhorst, J. J., Lacey, S. F., Lancaster, E., Vogl, D. T., Weiss, B. M., Dengel, K., Nelson, A., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci126397 · Cited by 778
“sBCMA increased overall as both responders and nonresponders developed progressive disease, though the 3 long-term responders maintained low sBCMA concentrations (Supplemental Figure 8), confirming serum sBCMA concentration as a useful adjunctive biomarker for assessing myeloma disease response and progression (7).”
BackgroundAli, S. A., Shi, V., Maric, I., Wang, M., Stroncek, D. F., Rose, J. J., Brudno, J. N., Stetler-Stevenson, M., Feldman, S. A., Hansen, B. G., et al. (2016) · Blood · doi:10.1182/blood-2016-04-711903 · Cited by 757
B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
Carpenter, R. O., Evbuomwan, M. O., Pittaluga, S., Rose, J. J., Raffeld, M., Yang, S., Gress, R. E., Hakim, F. T., & Kochenderfer, J. N. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2422 · Cited by 653
Zhao, W.-H., Liu, J., Wang, B.-Y., Chen, Y.-X., Cao, X.-M., Yang, Y., Zhang, Y.-L., Wang, F.-X., Zhang, P.-Y., Lei, B., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0681-6 · Cited by 518
Metadata
- Authors
- Sanchez, E., Li, M., Kitto, A., Li, J., Wang, C. S., Kirk, D. T., Yellin, O., Nichols, C. M., Dreyer, M. P., Ahles, C. P., Robinson, A., Madden, E., Waterman, G. N., Swift, R. A., Bonavida, B., Boccia, R., Vescio, R. A., Crowley, J., Chen, H., & Berenson, J. R.
- Venue
- British Journal of Haematology
- Publisher
- Wiley
- Published
- 2012-07-18
- Volume
- 158
- Issue
- 6
- Pages
- 727-738
- ISSN
- 0007-1048 (ISSN-L)
- 1365-2141
- OpenAlex
- W2002048624
- Cited by
- 279
- References
- 44
- FWCI
- 2.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.